Minovia Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2011-07-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.minoviatx.com
Clinical Trials
7
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers
Recruiting
- Conditions
- Primary Mitochondrial Diseases
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06474104
- Locations
- 🇮🇱
Sheba Medical Center - Tel Ashomer, Ramat Gan, Israel
A Study to Evaluate the MNV-201 in Patients with Low Risk MDS
Phase 1
Recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Biological: MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06465160
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome
Active, not recruiting
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06144515
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06017869
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
Phase 1
Withdrawn
- Conditions
- Primary Mitochondrial Diseases
- Interventions
- Procedure: Bone Marrow mobilizationProcedure: ApheresisBiological: MNV-BM-PLC infusion
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Minovia Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04548843
- Locations
- 🇮🇱
Sheba Medical Center - Tel Ashomer, Ramat Gan, Israel
- Prev
- 1
- 2
- Next
News
No news found